Annexin Pharmaceuticals AB (publ) (ANNX.ST)

SEK 0.43

(-1.61%)

Market Cap (In SEK)

228.64 Million

Revenue (In SEK)

-

Net Income (In SEK)

-44.05 Million

Avg. Volume

652.85 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.203-0.932
PE
-
EPS
-
Beta Value
1.06
ISIN
SE0009664154
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Anders Haegerstrand M.D., Ph.D.
Employee Count
-
Website
https://www.annexinpharma.com/sv
Ipo Date
2017-04-19
Details
Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation. The company was founded in 2014 and is based in Stockholm, Sweden.